STOCK TITAN

Crescent Biopharma: Balyasny reports about 4.34% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Crescent Biopharma, Inc. (CBIO) is the issuer in an amended ownership report for an event dated September 30, 2026. Five reporting persons each report beneficial ownership of 1,611,958 common shares, approximately 4.34% of the class; these are the same shares attributed through their management relationships, not five separate positions.

The shares are held directly by Atlas Private Holdings (Cayman) Ltd. (670,000 shares) and Atlas Diversified Master Fund, Ltd. (941,958 shares). Balyasny Asset Management L.P. is their investment manager; BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny report deemed ownership through their respective roles in the management chain. Each reporting person lists sole voting and dispositive power over 1,611,958 shares and no shared power. The percentage is based on 37,143,940 shares outstanding as of July 27, 2026. The two direct holders are identified as entitled to dividends and sale proceeds.

Beneficially owned shares 1,611,958 shares Each of the five reporting persons reported this same share position.
Percent of class Approximately 4.34% Reported ownership percentage for each reporting person.
Shares outstanding 37,143,940 shares As of July 27, 2026; used as the basis for the reported percentage.
Atlas Private Holdings shares 670,000 shares Shares held directly by Atlas Private Holdings (Cayman) Ltd.
Atlas Diversified Master Fund shares 941,958 shares Shares held directly by Atlas Diversified Master Fund, Ltd.
beneficially own regulatory
"may be deemed to beneficially own such Shares"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
sole power to vote regulatory
"Sole power to vote or to direct the vote"
sole power to dispose regulatory
"Sole power to dispose or to direct the disposition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CBIO shares did the Balyasny reporting persons report?

Each of the five reporting persons reported beneficial ownership of 1,611,958 CBIO common shares, approximately 4.34% of the class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





38000Q201

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BALYASNY ASSET MANAGEMENT L.P.
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
BAM GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Balyasny Asset Management Holdings LP
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Dames GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:11/16/2026
Dmitry Balyasny
Signature:/s/ Dmitry Balyasny
Name/Title:Dmitry Balyasny / Self
Date:11/16/2026

Keep reading